Medpace Holdings (MEDP) Reveals “Shocking” Bookings Miss, Shares Fall - Hagens Berman

Core Insights - Medpace Holdings, Inc. is under investigation by Hagens Berman due to concerns over its financial performance and public statements, particularly regarding its growth assurances that were contradicted by its latest earnings report [1][3] Financial Performance - On July 23, Medpace reported a significantly lower-than-expected book-to-bill ratio for Q2, attributed to "elevated project cancellations," which has raised concerns among investors and analysts [2] - The unexpected results led to an 18% drop in Medpace's share price on the announcement day, described by William Blair analyst Max Smock as "shocking" and "alarming" due to the stark discrepancy from prior guidance [3] Investigation Details - Hagens Berman is investigating whether Medpace misled investors regarding the health of its business, with a focus on potential violations of U.S. securities laws [4] - The firm is encouraging individuals with knowledge of the situation or who have suffered losses to come forward and assist in the investigation [4]